Search Main Menu Main Content
  • Change contrast :
Retour à l'accueil du site de la HAS
logo HAS
icone
  • HAS profile
    • Mission
    • Organisational Structure
    • Ethics, transparency and management of conflicts of interest
  • International relations and projects
  • Publications
  1. root
  2. PLUVICTO (lutécium (177Lu) vipivotide tétraxétan)
  • icone plus
  • My account

    • Email alert Subscription
    • Newsletter Subscription
    • My search
    Refresh
    Please fill in your email address to retrieve your email alerts subscriptions.
    New subscription
    Please fill in your email address to retrieve your newsletter subscriptions.

    You do not have a saved search

    Mon Compte
  • No element in selection

    Favoris
  • Établissements de santé
  • Contact Abonnez-vous aux actualités
Listen Listen
Add to my selection
  • History
  • Technical informations
Share
Share on
Facebook share - facebook.com - new window
Tweeter share - Partager sur Twitter - twitter.com - new window
LinkedIn share - linkedin.com - new window
Print

PLUVICTO (lutécium (177Lu) vipivotide tétraxétan)

Medicine - Posted on May 06 2025
Active substance (DCI)
  • lutécium (177Lu) vipivotide tétraxétan
history (3)
  • 7/13/23

    PLUVICTO [177Lu] - Cancer de la prostate

    Renouvellement de l'autorisation d’accès précoce octroyée à la spécialité PLUVICTO (177Lu) dans l'indication « tEn associati...
    icône flèche
  • Economic analysis
    4/19/23

    PLUVICTO (lutetium (177Lu) vipivotide tetraxetan) - Prostate cancer

    First assessment. Key points Favourable opinion for reimbursement “in combination with androgen deprivation therapy (ADT) wi...
    CAV :
    54321
    icône flèche
  • 7/13/22

    PLUVICTO-[177Lu]Lu-PSMA-617 - Cancer de la prostate

    Autorisation d’accès précoce octroyée à la spécialité [177Lu]Lu-PSMA-617 1000 MBq/mL solution injectable/pour perfusion dans...
    icône flèche
Technical information
ATC code
  • V10XX05
Manufacturer
ADVANCED ACCELERATOR APPLICATIONS
Presentation

PLUVICTO 1000 MBq/mL, solution injectable pour perfusion
1 flacon en verre de 7,5 mL à 12,5 mL (CIP : 34009 550 925 1 3)

 

All our publications
    Drug therapy Genital cancers

Follow us :

  • Twitter (nouvelle fenêtre)
  • Facebook (nouvelle fenêtre)
  • Youtube (nouvelle fenêtre)
  • LinkedIn (nouvelle fenêtre)
Haute Autorité de Santé
Advancing quality in the fields of health and social care services
  • Eunetha.eu
  • Pasq.eu
  • All our publications by topic and type
  • Opinions on medicines
  • Opinions on medical devices
  • INAHTA briefs
  • Français
  • English
eNrFmF1v2jAUhu/5FVHuk5CSlnYKVBtrN6RWZbRo024qkxyKmbFTfwS6Xz+H0I1OjrqaurskTt5z4nP8nJekp+sl8UrgAjPa8+Ow7XtAM5ZjetfzJzfnwbF/2m+lC1Sindu6YTuMD3wvI0iInl+thlNAVITfLi8+gn4euN9veSmbLiCTT+5TEpPwMxLzS1RU93hpyXDuLUHOWd7zCyU3V71USK6z6K8Y/yEKlEEaba/sri5uk93raVSJ/YOqEsAvEL0zigK10swU50DlAEm4Y/yhId+OlTYWYxBM8QxGSM5HnJU4h9wYYoaIAKsgs1V+DbwkIKsgRvFokS2FlThaoPUY7ofmpN/r1YFcy6AdxN3kpNM+ipOTpNu1CsV3tspcBf0SUXHbSZJOEncioFFBVIkzyQKiJGRYLXUaXaKCEhe4ZFJvdiBBcrQGiahlBUeMS0Qc1Q6LwdP2cxSHw/2zPZJjURD0EC5EYbtViCO9DFxDwt2LVG9wwzW2iN6zv/SpIiR6YdaTLVQcZVwxa8AUlQ1sOR/bbsSAUQnr5ora4VCut72IQbye7E9GzaNgpKYEZ7bg02hSIORkPGzm3tsj4wMSMOHumPEV05ytxOuzaLf2jrIvNjg1ihY8j28PTo6P4sND66P2XTdaw7Q6U5wVEGlKYbEPfIZ0xvbFju5ds9Rj575x026cFcsQgQZvFVhySnfroxV0dh7cnbV6wSj66ezGtom+KOAP15ufRmmc936X3w7iLiaDbtnGxF9+AGoOOHHdipv5MpeyEO+iaLVahXMkAoH0LoUz/p+mxM74dvfPwIlHqD1TTVpHqU/rEfqyOtqex+dcxL7OePv81oEbY0iuYI9a1Oh2Btjh2esz+48tdpb26Alj3IXZWFgkMaOuTJOamh3TXlNC15Wecw2Iq9kMN3ypaezLNKq/EvVbaVR9Ieq3fgG8Wx+J
L0yQNJYHSamPY22W